CD274 and non-small cell lung carcinoma: This study demonstrated that higher level of HMGB1 (≥ 3.83 ng/mL) is significantly associated with higher ORR and longer PFS in patients with NSCLC who underwent anti-PD-1/PD-L1 antibody monotherapy.